Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

por Genovese, Mark, Westhovens, Rene, Meuleners, Luc, Van der Aa, Annegret, Harrison, Pille, Tasset, Chantal, Kavanaugh, Arthur
Publicado 2018

GLPG1205, a GPR84 Modulator: Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects

por Timmis, Helen, Van Kaem, Tim, Desrivot, Julie, Dupont, Sonia, Meuleners, Luc, Beetens, Johan, Helmer, Eric, Santermans, Eva, Huettner, Silke
Publicado 2021

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK‐1 Inhibitor, After Short‐Term Treatment of Rheumatoid Arthritis: Results of Two Randomized P...

por Vanhoutte, Frédéric, Mazur, Minodora, Voloshyn, Oleksandr, Stanislavchuk, Mykola, Van der Aa, Annegret, Namour, Florence, Galien, René, Meuleners, Luc, van 't Klooster, Gerben
Publicado 2017

Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)

por Orbai, Ana-Maria, Ogdie, Alexis, Gossec, Laure, Tillett, William, Leung, Ying Ying, Gao, Jingjing, Trivedi, Mona, Tasset, Chantal, Meuleners, Luc, Besuyen, Robin, Hendrikx, Thijs, Coates, Laura C
Publicado 2020